Victoria Johnson

Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.

Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.

Yee discussed how the data show a benefit in this hard-to-treat population, similarly to the heterogeneous FSGS group.

Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.

After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.

Overall, 8 of 20 patients had complete or partial remission of their FSGS.

The data, which will be presented at a later time, may enable regulatory submission for accelerated approval to the FDA.

Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.

Ustekinumab-aekn is set to enter the US market no later than February 21, 2025, as per a settlement and license agreement between Janssen, Teva, and Alvotech.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

Findings from the study also continued to support a positive Ara h 2-sIgE as the single most important predictor of peanut allergy.

Compared with older nomenclature, MASLD was significantly associated with severe artery calcification.

The burden of LC-MASLD has significantly increased, especially in economically disadvantaged countries.

The anti-TFPI significantly reduced ABR compared to routine prophylaxis treatment in the phase 3 BASIS trial.

Second-generation long-acting injectables were particularly underutilized, and especially among older patients.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

BSC and Fresnius Kabi reached a deal facilitated by Evio Pharmacy Solutions by sidestepping pharmacy benefit managers.

The biosimilars month in review highlights a new approval and 2023 cost savings

A new post-hoc analysis has also revealed improvements in quality of life in patients’ caregivers.

Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.

The approval marks the fourth biosimilar approved for ustekinumab, for all approved indications.

To date, biosimilars have supported 495 million incremental days of therapy that patients would otherwise not have received.

Participants in a study in China also experienced comparable safety and immunogenicity.

The biosimilars month in review highlights recent data demonstrating clinical equivalence and efforts to improve their access.

The FDA approved neffy for treating severe allergic reactions in people over 33 kg in August 2024.

Patients receiving Humira or Hulio had the highest satisfaction levels across different measures.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

There were no significant differences in the overall incidence of AEs and serious AEs.

Rates of adverse events leading to discontinuation were similar between populations of moderate-to-severe psoriasis and psoriatic arthritis.

Adoption rates of infliximab biosimilars only sped up after introduction of a third biosimilar.